{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:18Z","timestamp":1792699998084,"version":"4.5.0"},"reference-count":81,"publisher":"Massachusetts Medical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2019,1,3]]},"DOI":"10.1056\/nejmra1705346","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T17:01:36Z","timestamp":1546448496000},"page":"57-70","source":"Crossref","is-referenced-by-count":287,"title":["Treating Disease at the RNA Level with Oligonucleotides"],"prefix":"10.1056","volume":"380","author":[{"given":"Arthur A.","family":"Levin","sequence":"first","affiliation":[{"name":"From Research and Development, Avidity Biosciences, La Jolla, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.1.280"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208760"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609243"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701329"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400283"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31009-1"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405760"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1995.1111"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1276"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2008.09.017"},{"key":"e_1_3_3_14_2","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.","volume":"45","author":"Koenig M","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989;45:498-506.2491009","journal-title":"Am J Hum Genet"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0682"},{"key":"e_1_3_3_16_2","unstructured":"Eteplirsen briefing document NDA 206488. Cambridge MA: Sarepta Therapeutics January 22 2016 (https:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/peripheralandcentralnervoussystemdrugsadvisorycommittee\/ucm481912.pdf)."},{"key":"e_1_3_3_17_2","unstructured":"FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. Press release of the Food and Drug Administration September 19 2016 (https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm)."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1996.0010"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M107632200"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.08.002"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0050073"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.212407"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201207087"},{"key":"e_1_3_3_24_2","unstructured":"FDA approves first drug for spinal muscular atrophy. Press release of the Food and Drug Administration December 23 2016 (https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm534611.htm)."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.11.069"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.606442"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60284-X"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.04.013"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1614154"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604304"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.6.1340"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/bit.21798"},{"key":"e_1_3_3_35_2","first-page":"305","volume-title":"Oligonucleotides","author":"Behlke MA","year":"2008","unstructured":"Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-319.19025401"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.21.12631"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.3.1617"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2007.179"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.11.002"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12961"},{"key":"e_1_3_3_41_2","unstructured":"Advisory Committee briefing materials: available for public release \u2014 drisapersen briefing document NDA 206031. Novato CA: Biomarin November 24 2015 (https:\/\/wayback.archive-it.org\/7993\/20170405224839\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee\/UCM473738.pdf)."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3586"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1310"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601877"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209367109"},{"key":"e_1_3_3_46_2","unstructured":"FDA briefing document for the Peripheral and Central Nervous System Drugs Advisory Committee: drisapersen. November 24 2015 (https:\/\/wayback.archive-it.org\/7993\/20170405224801\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee\/UCM473737.pdf)."},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","unstructured":"Crooke ST Baker BF Pham NC et al. The effects of 2\u2032-O -methoxyethyl oligonucleotides on renal function in humans. Nucleic Acid Ther 2018;28:10-22.29185862","DOI":"10.1089\/nat.2017.0693"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.02.359"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12738"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0650"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2016.12.003"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.06.036"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08956"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8321"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1285"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.05.019"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1807"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22341"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1596"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.02.037"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.06.122"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.22"},{"key":"e_1_3_3_63_2","doi-asserted-by":"crossref","unstructured":"Li L-C ed. RNA activation. Singapore: Springer 2017.","DOI":"10.1007\/978-981-10-4310-9"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-4310-9_11"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.018"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2015.4"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060208-105251"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1306243110"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biophys-062215-010822"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaq0180"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.72"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.09.012"},{"key":"e_1_3_3_73_2","article-title":"Identification of pre-existing adaptive immunity to Cas9 proteins in humans.","author":"Charlesworth CT","year":"2018","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, et al. Identification of pre-existing adaptive immunity to Cas9 proteins in humans. bioRxiv. January 5, 2018.","journal-title":"bioRxiv"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2661"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2978"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2843"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209026"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805038105"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12734"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.3892\/br.2017.900"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23922"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2521"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMra1705346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T21:14:09Z","timestamp":1711487649000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMra1705346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,3]]}},"alternative-id":["10.1056\/NEJMra1705346"],"URL":"https:\/\/doi.org\/10.1056\/nejmra1705346","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]}}}